Biogen Inc. (BIIB)

Over the past six months, Biogen's stock price has increased by 18.01%. Key events include the release of fourth-quarter and full-year 2025 financial results on February 6, 2026, with a GAAP diluted EPS of $(0.33) and Non-GAAP diluted EPS of $1.99. On March 30, 2026, the FDA approved a new high-dose regimen of SPINRAZA for Spinal Muscular Atrophy. Biogen announced a proposed acquisition of Apellis Pharmaceuticals on March 31, 2026. Positive Phase 2 trial results for Litifilimab in Cutaneous Lupus Erythematosus were announced on March 28, 2026. Biogen projected a $34 million Q1 2026 in-process R&D expense on April 6, 2026. On April 10, 2026, the stock price was $172.97, down 2.34% for the day, but up 50.19% over the past year.

There is some indication of demand seasonality for Biogen's products. The first quarter of the year has been noted as a seasonally weaker quarter for the MS business, influenced by factors such as higher discounts, allowances, and channel dynamics. Sales growth for Spinraza has also been described as moderate in the U.S. market, with pricing pressure and competition impacting sales in ex-U.S. markets. Biogen's management of inventory also suggests that customer demand can fluctuate.

Biogen Inc. is a multinational biotechnology company focused on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its product portfolio includes treatments for multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). Key products include Tecfidera, Vumerity, AVONEX, Plegridy, Tysabri for MS; Spinraza for SMA; Skyclarys for Friedreich's ataxia; Qalsody for ALS; and Fumaderm for severe plaque psoriasis. The company also produces five biosimilars and collaborates with Genentech for drugs like Rituxan, Gazyva, and Ocrevus.

Biogen's global headquarters are in Cambridge, Massachusetts, with innovation hubs and R&D teams in Cambridge and South San Francisco, CA. Its largest manufacturing campuses are in Wake and Durham counties in North Carolina. Biogen's therapies are available in over 80 countries and through its Expanded Access Program.

Biogen is recognized for its pioneering science and commitment to delivering innovative medicines for complex and devastating diseases, particularly in neurology. The company emphasizes advancing health equity and has been listed on Forbes' "America's Best Companies" and "Global 2000" lists. Events affecting Biogen's reputation include the acquisition of Reata Pharmaceuticals in July 2023, followed by job cuts, and the acquisition of Human Immunology Biosciences (HI-Bio) in May 2024. The company's 2025 Annual Report acknowledges risks related to reputational harm. Biogen is focused on new product launches and educating providers and patients about these treatments.

Biogen Inc. is primarily owned by institutional shareholders, who hold 95.20% of the company. Individual insiders own 2.16%, and retail investors hold 2.63%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Primecap Management Co/ca/, Fmr Llc, and State Street Corp. Other significant institutional holders include Geode Capital Management, Llc, Wellington Management Group Llp, Point72 Asset Management, L.P., Norges Bank, and Morgan Stanley.